Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Deferred Revenue (2016 - 2023)

Spyre Therapeutics (SYRE) has disclosed Current Deferred Revenue for 5 consecutive years, with $930000.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Current Deferred Revenue rose 210.0% year-over-year to $930000.0, compared with a TTM value of $930000.0 through Jun 2023, up 210.0%, and an annual FY2022 reading of $517000.0, down 78.08% over the prior year.
  • Current Deferred Revenue was $930000.0 for Q2 2023 at Spyre Therapeutics, up from $302000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $19.2 million in Q1 2021 and bottomed at $300000.0 in Q2 2022.
  • Average Current Deferred Revenue over 3 years is $3.9 million, with a median of $1.6 million recorded in 2021.
  • The sharpest move saw Current Deferred Revenue crashed 94.55% in 2022, then skyrocketed 210.0% in 2023.
  • Year by year, Current Deferred Revenue stood at $2.4 million in 2021, then crashed by 78.08% to $517000.0 in 2022, then skyrocketed by 79.88% to $930000.0 in 2023.
  • Business Quant data shows Current Deferred Revenue for SYRE at $930000.0 in Q2 2023, $302000.0 in Q1 2023, and $517000.0 in Q4 2022.